Delving into the Latest Updates on Recombinant human FSH(LG Chem Ltd.) with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms

Follitrope, Recombinant human FSH, rh-FSH

+ [4]

Target

FSHR

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Infertility, Female

Inactive Indication-

Originator Organization

LG Chem Ltd.

Active Organization

LG Chem Ltd.

Icon Clinical Research (Beijing) Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (07 Apr 2021),

Infertility, Female

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 3253

Sequence Code 3246

The present study investigated the adsorption of diclofenac sodium (DCF) and carbamazepine (CBZ) on carbon-silica composites (CSC), activated carbon (RH-AC) and biogenic silica (RH-BS) based on rice husks from aqueous solutions. The materials were characterised using scanning electron microscopy, infrared spectroscopy, inductively coupled plasma optical emission spectroscopy, nitrogen sorption and elemental analysis. These methods provided essential information on the morphology, chemical composition, textural properties and surface characteristics of porous materials. The results of the adsorption studies demonstrate that the investigated materials exhibit varying adsorption capacities for DCF and CBZ. The maximum adsorption capacity was achieved by CSCs, with 1111 mg g^-1 for DCF and 455 mg g^-1 for CBZ and indicates additive effects on the adsorption capacity of CSCs compared to RH-AC and RH-BS. In addition to the hydrogen bonds and the π-π electron donor-acceptor interactions of the carbon component, further hydrogen bonds are formed by the silanol groups of the silica component. The CSCs derived from rice husks represent an innovative approach to the more efficient removal of pharmaceutical residues from wastewater. This is accomplished by utilizing a single starting material for both components, thereby yielding a unique structural combination.

01 Dec 2024·Archives of Medical Research

Follicle-stimulating hormone sweetness: How carbohydrate structures impact on the biological function of the hormone

Review

Author: Dias, James A. ; Ulloa-Aguirre, Alfredo ; Llamosas, Regina ; Dias, James A

Follicle-stimulating hormone (FSH), or follitropin, exists in multiple molecular forms due largely to its protein-carbohydrate composition and the complexity of the glycans attached to the protein core. The heterogeneity of gonadotropins exists in two forms, macroheterogeneity, which results from the absence of one or two oligosaccharide chains in the ß-subunit, and microheterogeneity which results from variation in the structures and complexity of the glycans attached to the hormone. In the clinical arena, FSH compounds are widely used by fertility specialists to promote ovarian follicle growth and maturation to a preovulatory follicle containing a fertilization-competent oocyte. Several genetically engineered recombinant human FSH preparations have been added to the arsenal of follitropin preparations in several countries for the treatment of infertility, particularly in women attending assisted reproduction clinics. Although the primary structure of these recombinant proteins is identical to that of naturally occurring FSH, the cell context and variations in the production and purification processes may impact the glycosidic profile of the recombinant FSH macro- and micro-heterogeneity, which may potentially influence the pharmacokinetics and pharmacodynamics of the compound. This review concentrates on the structure-function correlates of follitropin, with emphasis on the physiological and biological importance of the carbohydrates attached to its protein core, including its pharmacokinetics and biological activity. Emphasis is placed on pituitary FSH, and the available data on the various recombinant FSH preparations employed in therapeutics are also discussed, considering that this gonadotropin represents the cornerstone for the treatment of infertility in modern assisted reproduction.

01 Jun 2024·Reproductive BioMedicine Online

Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35–40 years

Article

Author: Fischer, Robert ; Schwarze, Juan-Enrique ; Chuderland, Dana ; D'Hooghe, Thomas ; Bielfeld, Alexandra P ; Lispi, Monica ; Hayward, Brooke ; Verpillat, Patrice ; Krussel, Jan-Steffan

RESEARCH QUESTIONAccording to real-world data, is recombinant human FSH (r-hFSH) combined with recombinant human LH (r-hLH) or r-hFSH alone more effective for women of advanced maternal age (AMA) in terms of live birth?DESIGNNon-interventional study comparing the effectiveness of r-hFSH and recombinant r-hLH (2:1 ratio) versus r-hFSH alone for ovarian stimulation during ART treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register.RESULTSOverall clinical pregnancy (29.8%, 95% CI 28.2 to 31.6 versus 27.8%, 95% CI 26.5 to 29.2) and live birth (20.3%, 95% CI 18.7 to 21.8 versus 18.0%, 95% CI 16.6 to 19.4) rates were not significantly different between the combined r-hFSH and r-hLH group and the r-hFSH alone group (P = 0.269 and P = 0.092, respectively). Treatment effect was significantly higher for combined r-hFSH and r-hLH compared with r-hFSH alone for clinical pregnancy (33.1%, 95% CI 31.0 to 35.0 versus 28.5%, 95% CI 26.6 to 30.4; P = 0.001, not adjusted for multiplicity) and live birth (22.5%, 95% CI 20.5 to 24.2 versus 19.4%, 95% CI 17.6 to 20.9; P = 0.014, not adjusted for multiplicity) in a post-hoc analysis of women with five to 14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of combined r-hFSH and r-hLH for ovarian stimulation in women aged 35-40 years with normal ovarian reserve.CONCLUSIONSWomen of AMA with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials.

100 Deals associated with Recombinant human FSH(LG Chem Ltd.)

Login to view more data